Elagolix sodium, an oral short-acting nonpeptide gonadotropin-releasing hormone antagonist has been approved by the FDA at a dose of 300 mg twice daily with add-back therapy for up to 24 months.
Minimally invasive procedures for uterine fibroids are highly effective, but gaps in diagnosis, racial disparities, and lack of availability outside urban academic centers limit their use.